Table 1 Costs and utility used in the cost-effectiveness analysis model

cost

 Anastrozole(per mg)

£3.14(2.512–3.768)

$3.11(2.488–3.732)

Gamma

[17, 18]

 Breast cancer Laboratory assessment(twice a year)

£301.06(247.87–377.47)

$420(467.9–1,403.8)

Gamma

[19, 20]

 Breast cancer biopsy, one-time

£353.5(171.15–588)

$831(664.8–997.2)

Gamma

[21, 22]

 Imaging assessment of breast cancer(per year)(X/MRI)

£88.31(57.69–148.24)

$135(67.5–535)

Gamma

[21, 23]

 Outpatient management of breast cancer(twice a year)

£130(104–156)

$203.91(183.52–224.30)

Gamma

[24, 25]

 Surgical resection of breast cancer

£4,422(4,340–4,827)

$10,618(8,494.4–12,741.6)

Gamma

[23, 24]

 Chemotherapy for breast cancer(per month)

£5,504(4,403.2–6,604.8)

$4,835.85(4,546.29–5,556.57)

Gamma

[25, 26]

 Surgical resection of non melanoma

£885(708–1,062)

$2,507.1(1,141.99–16,761.27)

Gamma

[27, 28]

 Non-melanoma diagnosis

£224(179.2–268.8)

$2,493(2,397–2,590)

Gamma

[27, 29]

 Non-melanoma Laboratory assessment(twice a year)

£327(261.6–392.4)

$45(36–54)

Gamma

[27, 29]

Health utility value

 Invasive breast cancer

0.731(0.5848–0.8772)

Beta

[30]

 Non invasive breast cancer

0.79(0.632–0.948)

Beta

[30]

 Non-melanoma

0.905(0.85–0.95)

Beta

[31]

 High risk women

0.99(0.9405–1)

Beta

[32]